Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
IL-10–producing and naturally occurring CD4+ Tregs: limiting collateral damage
Anne O’Garra, … , Paulo Vieira, Anne E. Goldfeld
Anne O’Garra, … , Paulo Vieira, Anne E. Goldfeld
Published November 15, 2004
Citation Information: J Clin Invest. 2004;114(10):1372-1378. https://doi.org/10.1172/JCI23215.
View: Text | PDF
Review Series

IL-10–producing and naturally occurring CD4+ Tregs: limiting collateral damage

  • Text
  • PDF
Abstract

Effective immune responses against pathogens are sometimes accompanied by strong inflammatory reactions. To minimize damage to self, the activation of the immune system also triggers anti-inflammatory circuits. Both inflammatory and anti-inflammatory reactions are normal components of the same immune response, which coordinately fight infections while preventing immune pathology. IL-10 is an important suppressive cytokine, produced by a large number of immune cells in addition to the antigen-driven IL-10–producing regulatory and the naturally occurring suppressor CD4+ T cells, which is a key player in anti-inflammatory immune responses. However, additional mechanisms have evolved to ensure that pathogen eradication is achieved with minimum damage to the host. Here we discuss those mechanisms that operate to regulate effector immune responses.

Authors

Anne O’Garra, Pedro L. Vieira, Paulo Vieira, Anne E. Goldfeld

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Layers of regulation of the immune response. At low levels of inflammati...
Layers of regulation of the immune response. At low levels of inflammation (A) both Foxp3+ naturally occurring Tregs and Foxp3– IL-10 Tregs inhibit CD4+ T cell proliferation through IL-10–independent, cell contact–dependent mechanisms. (B) Similar mechanisms may control immune responses to self antigens and autoimmune pathologies associated with low-level inflammation such as gastritis. (C) When strong inflammation occurs, with activation of APCs, effector molecules, such as IL-10 and TGF-β, secreted by Tregs are required to control CD4+ T cell responses. TLR, Toll-like receptor.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts